Effectiveness, safety, and treatment adherence of biosimilar follow-on insulin in diabetes management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35670655/
Aims: The purpose of this study was to assess the change in HbA 1c after initiation of biosimilar follow-on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2...
Conclusions: In patients with type 2 diabetes, Basaglar provided similar glycemic control compared to Lantus, had similar safety profile and lower drug costs, and demonstrated more favorable adherence.
Blocking C3d+/GFAP+ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116904/
Qi Zhang, 1 , # Chang Liu, 1 , # Rubing Shi, 1 Shiyi Zhou, 1 Huimin Shan, 1 Lidong Deng, 1 Tingting Chen, 1 Yiyan Guo, 1 Zhijun Zhang,...
Conclusion: We concluded that astrocytes undergo a phenotypic shift over time after ischemic stroke. C3d /GFAP astrocytes aggravate BBB disruption, suggesting that inhibiting C3d /GFAP astrocyte formation represents a novel strategy for the treatment of ischemic stroke.
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35653929/
Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical...
Conclusions: Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical trials should encourage clinicians to prioritize oral semaglutide over other antidiabetic agents.
Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study - Diabetes Therapy
Source : https://link.springer.com/article/10.1007/s13300-022-01273-5
Background and Aim Diabetes reduces the levels of circulating endothelial progenitor cells (EPCs), which contribute to vascular homeostasis. In turn, low EPCs levels predict progression of chronic complications. Several studies...
Conclusion: In individuals hospitalized for decompensated diabetes, insulin therapy rapidly increases EPC levels for up to 2 months. EPC defect, reflecting impaired vascular repair capacity, may be reversible in the early diabetes stages.
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122001229?via=ihub
Effective, safe, and easily accessible antidiabetics with cardiovascular protection are much needed in India. * Oral semaglutide has better glycemic and weight control and decreases CV risk, best suited for...
Conclusions: Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical trials should encourage clinicians to prioritize oral semaglutide over other antidiabetic agents.